Vaccine against hepatitis a comprising simian HAV isolate AGM-27
US5476658A · kind A · utility
6Cited by
1References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 26, 1991 |
| Grant date | Dec 19, 1995 |
| Priority date | — |
| Expiry date | Mar 26, 2011 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/825
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian hepatitis A viral isolate AGM-27; a pharmaceutical composition comprising the simian hepatitis A viral isolate AGM-27; a method of preventing hepatitis A in an animal; and a vaccine comprising the simian hepatitis A viral isolate AGM-27.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.